Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Inclusion Criteria

• •Male or female patients \> 18 years of age
• •Patients with histologically confirmed BRAFV600E melanoma (Stage IIIC or
• •Stage IV, American Joint Commission on Cancer)
• •Eastern Cooperative Oncology Group Performance Status of 0 to 2
• •Life expectancy \> 3 months
• •At least 1 site of radiographically measurable disease by RECIST 1.1
• •Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing:
• •Absolute neutrophil count \> 1.0 x 10⁹/L
• •Platelet count \> 50 x 10⁹/L
• •Hemoglobin \> 8 g/dL
• •Serum creatinine \< 2 x upper limit of normal
• •Total serum bilirubin \< 3 x ULN
• •Serum aspartate transaminase or serum alanine transaminase \< 3 x ULN, and \< 4 x ULN if liver metastases are present
• •Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician
• •Pre-menopausal females and females \< 2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of the study drug
• •Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for \> 1 year
• •Before study entry, written informed consent must be obtained from the patient prior to performing any study related procedures